TL;DR: The Centers for Medicare & Medicaid Services modified NCD 152 governing Medicare coverage of Prostate Specific Antigen (PSA) testing, effective March 7, 2026. Here's what billing teams need to do.
CMS's NCD 152 is the National Coverage Determination that governs Medicare reimbursement for PSA testing — a diagnostic laboratory test used in prostate cancer detection, post-treatment monitoring, and metastatic disease surveillance. The policy was modified as of March 7, 2026, and while the clinical framework stays largely intact, the frequency limitations and indication-specific criteria carry real claim denial risk if your documentation doesn't align precisely. The policy does not list specific CPT or HCPCS codes in the current version, so you'll need to cross-reference the quarterly Covered Code Lists linked in the policy and the Medicare Claims Processing Manual, Chapter 120.
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Prostate Specific Antigen |
| Policy Code | NCD 152 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Urology, Oncology, Primary Care, Clinical Laboratory |
| Key Action | Audit documentation for PSA claims to confirm indications and frequency limits are clearly supported before March 7, 2026 |
CMS PSA Testing Coverage Criteria and Medical Necessity Requirements 2026
CMS covers PSA testing under NCD 152 across several distinct clinical scenarios — but the coverage policy is tighter than it looks. The medical necessity criteria are indication-specific, and frequency limits apply. Getting this wrong means denied claims.
The clearest covered indication is men presenting with lower urinary tract signs or symptoms. CMS specifically names hematuria, slow urine stream, hesitancy, urgency, frequency, nocturia, and incontinence as qualifying presentations. PSA is also covered for patients with a palpably abnormal prostate on physical exam, or when other laboratory or imaging studies suggest a malignant prostate disorder.
Post-diagnosis, PSA serves as a covered monitoring tool. Once prostate cancer is diagnosed, CMS recognizes PSA as a marker for following tumor progress, detecting metastatic disease, and identifying persistent disease in patients who may need additional treatment. This includes post-radical prostatectomy monitoring — CMS notes PSA becomes a sensitive indicator of persistent disease three to six months after surgery — and post-antiandrogen therapy monitoring, where PSA at six months can distinguish favorable from limited treatment response.
PSA testing is also covered for differential diagnosis in men presenting with undiagnosed disseminated metastatic disease. That's a narrower, more specific use case than routine screening, and your documentation needs to reflect that distinction clearly.
Prior authorization is not explicitly mentioned in NCD 152 for PSA testing. But that doesn't mean your MAC won't impose additional requirements — check with your local Medicare Administrative Contractor before assuming prior auth is off the table for high-frequency billing patterns.
CMS PSA Testing Exclusions and Non-Covered Indications
The frequency limitations in NCD 152 function as soft exclusions — exceed them without documented justification and you're looking at a denied claim.
For patients with lower urinary tract signs or symptoms, PSA is covered once per year unless there is a documented change in the patient's medical condition. That phrase — "change in medical condition" — is doing a lot of work. Your documentation needs to explicitly state what changed, not just reorder the test.
For patients with a diagnosis of in situ carcinoma, the limit is even tighter. CMS covers the test once, full stop — unless the result is abnormal, in which case one additional test is covered. Two PSA tests for a patient with in situ carcinoma and a normal first result is a denial waiting to happen.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Lower urinary tract signs/symptoms (hematuria, slow stream, hesitancy, urgency, frequency, nocturia, incontinence) | Covered | See quarterly Covered Code Lists | Once per year; additional testing requires documented change in medical condition |
| Palpably abnormal prostate on physician exam | Covered | See quarterly Covered Code Lists | Standard medical necessity documentation required |
| Other lab or imaging suggesting malignant prostate disorder | Covered | See quarterly Covered Code Lists | Document supporting studies clearly |
| Post-diagnosis tumor marker / monitoring prostate cancer progression | Covered | See quarterly Covered Code Lists | Covers detection of metastatic or persistent disease |
| Post-radical prostatectomy (3–6 months) | Covered | See quarterly Covered Code Lists | Sensitive indicator of persistent disease per CMS |
| Post-antiandrogen therapy (6 months) | Covered | See quarterly Covered Code Lists | Distinguishes favorable vs. limited response |
| Differential diagnosis for undiagnosed disseminated metastatic disease | Covered | See quarterly Covered Code Lists | Narrow indication — documentation must reflect this clinical scenario |
| In situ carcinoma — initial test | Covered | See quarterly Covered Code Lists | Once per diagnosis unless result is abnormal |
| In situ carcinoma — repeat test after abnormal result | Covered (once) | See quarterly Covered Code Lists | One repeat only |
| In situ carcinoma — repeat test after normal result | Not Covered | See quarterly Covered Code Lists | Exceeds frequency limit; claim will deny |
CMS PSA Testing Billing Guidelines and Action Items 2026
These are concrete steps your billing team and practice managers should complete before March 7, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the current quarterly Covered Code Lists from CMS. NCD 152 does not list specific CPT or HCPCS codes in the policy text — the codes live in the quarterly Covered Code Lists referenced at the bottom of the policy. If your charge capture is running on outdated codes, your claims are at risk from day one. Get the current list now and confirm your EHR or billing system is using the right codes. |
| 2 | Audit your PSA claim frequency by patient. Run a report on PSA claims submitted in the past 12 months. Flag any patients where PSA was billed more than once annually for a lower urinary tract indication. For each flagged claim, confirm the medical record documents a specific change in medical condition — not just a repeat order. |
| 3 | Create a hard stop or documentation prompt for in situ carcinoma patients. For patients with a diagnosis of in situ carcinoma, your workflow should flag any second PSA order. If the first result was normal, the second test is not covered. If the first result was abnormal, one repeat is covered. Build that logic into your order entry or billing review process before March 7, 2026. |
| 4 | Review and standardize documentation templates for medical necessity. CMS is explicit about which clinical presentations qualify. Your ordering providers need to document the specific signs or symptoms — don't rely on a generic "prostate evaluation" note. Templates should pull from CMS's own language: hematuria, hesitancy, urgency, palpable abnormality, supporting imaging, and so on. |
| 5 | Cross-reference Chapter 120 of the Medicare Claims Processing Manual. NCD 152 explicitly points to the Medicare Claims Processing Manual, Chapter 120 (Clinical Laboratory Services Based on Negotiated Rulemaking) for claims processing instructions. If your billing team hasn't reviewed that chapter recently, do it before the effective date. If you're unsure how the updated policy intersects with your payer mix or MAC's local policies, loop in your compliance officer before March 7. |
| 6 | Check with your MAC for any local coverage policies that overlay NCD 152. National Coverage Determinations set the floor, but your MAC can add requirements on top. A policy that looks clean at the national level may have additional prior authorization or documentation requirements at the local level. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for PSA Testing Under NCD 152
NCD 152 does not include a specific list of CPT, HCPCS, or ICD-10 codes within the policy document itself. CMS publishes applicable codes through quarterly Covered Code Lists, which are linked directly from the policy page.
How to Access the Applicable Codes
Go to the NCD 152 policy page and scroll to the quarterly Covered Code Lists section. CMS updates these lists quarterly, so the codes in effect on March 7, 2026 may differ from what was billed in prior quarters.
Do not rely on codes from a prior quarter's list without verifying the current version. A code that was covered last quarter can drop off the list without a corresponding policy text change — and that's how clean-looking claims end up denied.
The policy also cross-references the Medicare Claims Processing Manual, Chapter 120 for additional claims processing guidance. Review that chapter alongside the Covered Code Lists, not instead of it.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.